You are here
Aleafia Labs Partners on Cannabinoid Pharmacogenetics Study
Study with G420, US-Based AKESOgen aimed at producing genetic tools for improved medical cannabis therapy
TORONTO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aleafia Labs, a division of Aleafia Health Inc. (TSXV: ALEF: OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) and Guided 420 Genetics Inc. (“G420”) with U.S.-based AKESOgen, Inc., (“AKESOgen”), together the (“Parties”), are announcing the commencement of a joint study (“the Study”) on cannabinoid pharmacogenetics in medical cannabis therapy. The initial 200 patient study will focus on developing medical cannabis patient genetic screening tools in the areas of THC-CBD sensitivity and metabolism, Endocannabinoid Deficiency Syndrome and cannabis treatment safety and adverse event risk.
This initiative will be funded by G420 and will be administered by Aleafia physicians practicing within the Canabo Medical Clinic network. The Study is expected to generate unique intellectual property assets that can be used towards proprietary product development and tools to improve medical cannabis treatment of major illnesses. It is expected that this study will lead to additional clinical investigations and larger retrospective cohort studies as well as prospective clinical trials based on the indications generated.
“Aleafia is pleased to partner with G420/AKESOgen in a first of its kind cannabis related pharmacogenomics study,” said Aleafia President of Clinic Operations, Dr. Gary Goodyear. “Aleafia’s unique medical cannabis clinic business perfectly complements a robust clinical research strategy that should yield benefits to patients through the form of improved treatment methods and product development.”
“Utilizing pharmacogenetics to better manage safety and efficacy for the administration of medical cannabis in a precise manner is a large unmet need in a fast-growing industry,” added Dr. Mark Bouzyk, AKESOgen’s Chief Scientific Officer. “The combination of G420/AKESOgen’s resources and expertise in genetic analysis and genomic study management combined with Aleafia’s leading clinical footprint in Canada’s medical cannabis sector has very exciting potential for new knowledge and therapy applications in this rapidly developing field.”
“Effective genetic screening tools have the potential to dramatically improve patient outcomes through more accurate dosing and treatment targeting,” said Aleafia Chief Medical Officer Dr. Michael Verbora. “This includes application in opioid replacement therapy and chronic illness treatment such as those currently used for cancer.”
For Investor & Media Relations, please contact:
Nicholas Bergamini, VP Public Affairs
About Aleafia Labs:
Aleafia Labs, a division of Aleafia Health Inc. oversees research & development of unique, proprietary intellectual property and products in the cannabis field, with a focus on medical cannabis treatment and cultivation. Aleafia is uniquely differentiated as a medical cannabis company as the interaction between the business and patient does not end at the point of sale. Canabo physicians diagnose, treat and track patients throughout the entire treatment cycle, a process which has led to the Company amassing what the company believes is the largest medical cannabis data set in the world.
G420 is a company whose mission is to develop unique pharmacogenetics products in rapidly emerging personal health application markets. Pharmacogenetics is a key component in the growing trend towards more personalized medicine where individual genetics play a greater role in establishing drug treatments and therapies. G420’s partner is U.S.-based AKESOgen, a leading genomics analysis and genetic clinical trial company. AKESOgen maintains a state of the art CLIA compliant and CAP accredited laboratory with extensive experience managing and processing large scale DNA test programs in the U.S. and internationally.
Neither Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company's current expectations. When used in this press release, the words "estimate", "project", "belief", "anticipate", "intend", "expect", "plan", "predict", "may" or "should" and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release includes information relating to the implementation of Aleafia Health's business plan. Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the implementation of Aleafia Health's business plan and matters relating thereto, risks associated with the cannabis industry, competition, regulatory change, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company's common share price and volume. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.